Giant cell tumour of bone (GCTB) is a primary bone tumour that contains numerous very large, hyper-nucleated osteoclastic giant cells. Osteoclasts form from CD14 þ monocytes and macrophages in the presence of receptor activator of nuclear factor kappa B ligand (RANKL) and macrophage-colony stimulating factor (M-CSF). GCTB contains numerous growth factors, some of which have been reported to influence osteoclastogenesis and resorption. We investigated whether these growth factors are capable of substituting for M-CSF to support osteoclast formation from cultured human monocytes and whether they influence osteoclast cytomorphology and resorption. Vascular endothelial growth factor-A (VEGF-A), VEGF-D, FLT3 ligand (FL), placental growth factor (PlGF) and hepatocyte growth factor (HGF) supported RANKL-induced osteoclastogenesis in the absence of M-CSF, resulting in the formation of numerous TRAP þ multinucleated cells capable of lacunar resorption. Monocytes cultured in the presence of M-CSF, HGF, VEGF-A and RANKL together resulted in the formation of very large, hyper-nucleated (GCTB-like) osteoclasts that were hyper-resorptive. M-CSF and M-CSF substitute growth factors were identified immunohistochemically in GCTB tissue sections and these factors stimulated the resorption of osteoclasts derived from a subset of GCTBs. Our findings indicate that there are growth factors that are capable of substituting for M-CSF to induce human osteoclast formation and that these factors are present in GCTB where they influence osteoclast cytomorphology and have a role in osteoclast formation and resorption activity. The osteoclast is a multinucleated cell, which is formed from circulating mononuclear phagocyte precursors derived from the bone marrow. 1,2 It exhibits a number of specialised cytochemical and functional features, including the ability to carry out lacunar bone resorption. Increased osteoclast formation and activity is seen in a number of osteolytic bone and joint conditions, including notably giant cell tumour of bone (GCTB), a primary bone tumour, which contains numerous, very large, often hyper-nucleated osteoclastic giant cells that effect a considerable amount of bone resorption. 3, 4 Osteoclast differentiation from monocyte or macrophage precursors requires the presence of receptor activator of nuclear factor kappa B ligand (RANKL) and macrophage-colony stimulating factor (M-CSF). 5 The importance of M-CSF in osteoclast formation is evidenced by the fact that in op/op osteopetrotic mice, which have a mutation in the M-CSF gene, very few osteoclasts are found in bone and there is markedly decreased bone resorption. 6,7 M-CSF promotes several aspects of osteoclastogenesis including the proliferation and fusion of osteoclast precursors as well as osteoclasts and the expression of the RANKL receptor by these cells. [8] [9] [10] The effect of M-CSF on mature osteoclast resorption activity is controversial with both a decrease and increase in lacunar resorption being reported. [11] [12] [13] Although bone resorption is greatly decreased in op/op mice, a few osteoclasts can still be found in skeletal tissues; op/op mice can also undergo a spontaneous age-dependent recovery of osteoclastogenesis. 14,15 These observations suggest that one or more growth factors may be capable of substituting for M-CSF to induce osteoclast formation. This was confirmed in several studies where hepatocyte growth factor (HGF), vascular endothelial growth factor-A
The osteoclast is a multinucleated cell, which is formed from circulating mononuclear phagocyte precursors derived from the bone marrow. 1, 2 It exhibits a number of specialised cytochemical and functional features, including the ability to carry out lacunar bone resorption. Increased osteoclast formation and activity is seen in a number of osteolytic bone and joint conditions, including notably giant cell tumour of bone (GCTB), a primary bone tumour, which contains numerous, very large, often hyper-nucleated osteoclastic giant cells that effect a considerable amount of bone resorption. 3, 4 Osteoclast differentiation from monocyte or macrophage precursors requires the presence of receptor activator of nuclear factor kappa B ligand (RANKL) and macrophage-colony stimulating factor (M-CSF). 5 The importance of M-CSF in osteoclast formation is evidenced by the fact that in op/op osteopetrotic mice, which have a mutation in the M-CSF gene, very few osteoclasts are found in bone and there is markedly decreased bone resorption. 6, 7 M-CSF promotes several aspects of osteoclastogenesis including the proliferation and fusion of osteoclast precursors as well as osteoclasts and the expression of the RANKL receptor by these cells. [8] [9] [10] The effect of M-CSF on mature osteoclast resorption activity is controversial with both a decrease and increase in lacunar resorption being reported. [11] [12] [13] Although bone resorption is greatly decreased in op/op mice, a few osteoclasts can still be found in skeletal tissues; op/op mice can also undergo a spontaneous age-dependent recovery of osteoclastogenesis. 14, 15 These observations suggest that one or more growth factors may be capable of substituting for M-CSF to induce osteoclast formation. This was confirmed in several studies where hepatocyte growth factor (HGF), vascular endothelial growth factor-A (VEGF-A), placental growth factor (PlGF) and FLT3 ligand (FL) were shown to be capable of supporting osteoclastogenesis in the absence of M-CSF. [16] [17] [18] [19] These growth factors are abundant and widely distributed in human tissues and are thought to have a role in several neoplastic and inflammatory conditions, which affect bone and joint, including GCTB. 20 The effect of potential M-CSF substitute growth factors on human osteoclast formation and resorption is not well defined. There is contradictory evidence as to whether VEGF and FL independently support osteoclastogenesis. 17, [20] [21] [22] In this study we have analysed the effect of M-CSF and M-CSF substitute growth factors, both alone and in combination, on human monocyte-osteoclast differentiation. In addition, we have examined whether these growth factors are expressed in GCTB and whether they influence osteoclast cytomorphology and resorption activity.
MATERIALS AND METHODS Reagents
For all cultures alpha minimal essential medium (a-MEM) (Lonza, Wokingham, UK) was supplemented with 10% heatinactivated FBS, 50 IU/ml Penicillin, 50 mg/ml Streptomycin (Invitrogen, Paisley, UK) and 2 mM L-Glutamine (Lonza) (MEM/FCS). Human-M-CSF and anti-M-M-CSF antibody were purchased from R&D Systems (Abingdon, UK), RANKL and osteoprotegrin (OPG) from Peprotech (London, UK) and calcitonin from Sigma (Poole, UK). Imatinib and Sunitinib were purchased from Cayman Chemical (Ann Arbour, MI, USA) and BioVision (Milpitas, CA, USA), respectively. All cultures were maintained at 37 1C in 5% CO 2 .
Isolation and Culture of Human Monocytes Derived from Peripheral Blood Human monocytes were obtained by density gradient centrifugation of 50 ml of buffy coat cell preparation provided by the National Blood Transfusion Service (Bristol, UK). The buffy coat preparation was mixed with an equal volume of MEM and purified over Histopaque (Sigma-Aldrich, Dorset, UK). After centrifugation at 2250 r.p.m. for 25 min, the cell layer above the Histopaque was collected, suspended in MEM, and centrifuged at 1800 r.p.m. for 10 min. The cell pellet was resuspended in MEM and centrifuged again. Five milliliter of MEM/FBS was then added to the cell pellet and the number of cells counted in a haematocytometer following lysis of red blood cells with 5% (v/v) acetic acid. 5 Â 10 5 cells per well were plated immediately onto dentine slices and glass coverslips in 96-well tissue culture plates with 100 ml/well of MEM/FBS. After 3 h incubation, the dentine slices and glass coverslips were washed in MEM/FBS to remove any non-adherent cells, and transferred into 24-well tissue culture plates containing 1 ml of MEM/FBS. CD14 þ monocytes were cultured on coverslips and dentine slices for 14 and 21 days, respectively, in 1 ml of a-MEM±RANKL (50 ng/ml) in the presence and absence of the following growth factors, either alone or in combination and with/ without added anti-M-CSF antibody (100 ng/ml); M-CSF (25 ng/ml); VEGF-A (25 ng/ml); VEGF-C (25 ng/ml); VEGF-D (25 ng/ml); PlGF (25 ng/ml); FL (25 ng/ml); HGF (25 ng/ml).
Cytochemical and Immunophenotypic Assessment of Osteoclast Formation
Following incubation for 14 days, monocyte cultures on coverslips were fixed and stained for TRAP, and immunocytochemically for CD14 and CD51 as previously described. 2, 4 Multinucleated cells expressing TRAP and containing more than three nuclei were considered osteoclasts. Cell cultures and coverslips were fixed in acetone. Endogenous peroxidase activity was blocked with 3% hydrogen peroxide and a protein serum block (Dako, UK). This was followed by incubation with the monoclonal antibodies 23C6 (Serotec, Oxford, UK) and NCL-CD14 (Leica, UK) directed against CD51 and CD14 respectively.
Functional Characterisation of Human Osteoclasts
To determine the presence of F-actin rings, which provide evidence of osteoclast attachment to a mineralised substrate, 21-day monocyte cultures on dentine slices were fixed in 4% formalin, permeabilized with 0.5% Triton X-100 and stained in the dark with TRITC-conjugated phalloidin (0.5 mg/ml) and DAPI (20 ng/ml) (Sigma). Cells were visualised using a fluorescence microscope.
Evidence of lacunar resorption was determined in 21-day monocyte cultures on dentine slices. Adherent cells were removed from dentine slices following treatment with 1 N NH 4 OH and sonication. Lacunar resorption pits were visualised by light microscopy after staining with 0.5% (w/v) toluidine blue in 0.5% aqueous boric acid (w/v) (pH 7.2-7.4). The mean area resorbed was determined using Adobe Photoshop and Image J (National Institutes of Health, USA) software as previously described. 4 
Effect of M-CSF and M-CSF Substitutes on Mature Osteoclast Resorption
To investigate the effect of M-CSF and M-CSF substitutes on mature osteoclast resorption, osteoclasts were isolated directly from 11 GCTBs by curettage, as previously described 3, 4 and cultured on dentine slices for 48 h in the presence of M-CSF (25 ng/ml), HGF (25 ng/ml), VEGF (25 ng/ml), FL (25 ng/ml), PlGF (25 ng/ml) and RANKL (50 ng/ml), either alone or in combination. In addition, osteoclasts were isolated directly from two GCTBs and cultured on dentine slices for 48 h in the presence of growth factor receptor inhibitors including those for M-CSF and VEGF (Imatinib, 5 nM and Sunitinib, 1 nM).
Following incubation, the dentine slices were treated with 1 N NH 4 OH, stained with toluidine blue and the lacunar resorption surface area quantitifed as detailed above. Lacunar resorption values were expressed as a percentage of resorption relative to the plain control (ie, osteoclasts cultured in MEM/FCS with no added factors.). To ensure that the lacunar resorption data reflected osteoclast resorption activity and not a change in osteoclast number, the number of giant cells was counted after 48 h of incubation. No difference in osteoclast number was noted between experimental conditions and the plain control.
Immunophenotypic Expression of M-CSF and M-CSF Substitutes in GCTB Five microns sections were prepared from formalin-fixed, paraffin-embedded specimens of seven cases of GCTB received at the Nuffield Orthopaedic Centre, Oxford and from a tissue microarray (provided by Professor Burger, Westfalische Wilhmsuniversitai, Munster, Germany) containing tissue from 107 GCTB samples. These included conventional, locally aggressive tumours, two of which had resulted in 'metastatic' lung nodules. Malignant GCTBs were excluded from this study. Expression of M-CSF, HGF, VEGF, FL and PlGF was determined by immunohistochemistry using an indirect immunoperoxidase technique. M-CSF was detected using a rabbit monoclonal anti-M CSF antibody (ab528564, Abcam, Cambridge, UK) at 1:50 dilution for 1 h; HGF was detected using a goat polyclonal antibody (AF-294-NA, R&D Systems), at 1:100 dilution overnight; VEGF-A was detected using a mouse monoclonal antibody (MAB293, R&D Systems), at a 1:100 dilution overnight. FL was detected using a rabbit monoclonal antibody (ab-52648, Abcam), at a dilution of 1:100 for 1 h. PlGF was detected using a rabbit polyclonal antibody (ab-9542, Abcam), at a dilution of 1:500 for 1 h. RANKL was detected using a goat polyclonal antibody (sc-7627, Santa Cruz Biotechnology, USA), at 25 mg/ml for 1 h.
Messenger RNA (mRNA) Expression of M-CSF and M-CSF Substitutes To confirm mRNA expression of M-CSF and M-CSF substitutes in GCTB tissue, real-Time PCR (RT-PCR) was carried out to identify mRNA transcripts for M-CSF, VEGF-A, VEGF-D, PlGF, FL and HGF. Total RNA was extracted from tissue samples using RNAeasy (Qiagen) and treated with DNAase I (Invitrogen). Single-stranded cDNA was synthesised using the SuperScript VILO cDNA Synthesis Kit (Invitrogen). RT-PCR was performed with the Rotor-Gene 3000 (Corbett Research) and the Express SYBR GreenER Kit (qPCR Supermix Universal) (Invitrogen). The PCR cycling conditions were as follows: 50 1C 2 min, 95 1C 2 min, 95 1C 15 s, 60 1C 1 min for 40 cycles. QuantiTect real-time primer sets were designed by Qiagen. The catalogue numbers were as follows; M-CSF (QT00035224), VEGF-A (QT01682072), VEGF-D (QT00003997), FL (QT00000245), P1GF (QT00030688), HGF (QT01758988) and G3PDH (glyceraldehyde-3-phosphate dehydrogenase, QT01192646). G3PDH mRNA expression was used as a control. Positive control for cytokine mRNA expression was reactive lymph node tissue.
Statistical Analysis
Statistical significance was determined using Student's t-test for comparing paired samples or one-way ANOVA followed by Dunnet post hoc test for comparing all sample groups against one control group. P values o0.05 were considered significant. All figures are derived from at least three independent experiments and are plotted as mean±s.d. In order to minimise the effect of batch-to-batch variation of monocytes, TRAP and lacunar resorption data were normalised to the number of TRAP þ cells and lacunar resorption, respectively, noted in the positive control (ie, monocytes incubated with M-CSF (25 ng/ml) and RANKL (50 ng/ml)). Experiments were performed in triplicate unless otherwise stated. 
Effect of M-CSF and M-CSF Substitute Growth Factors on Lacunar Resorption by GCTB-Derived Osteoclasts
The addition of M-CSF or the M-CSF substitutes alone to GCTB-derived osteoclasts cultured on dentine slices had no effect on total lacunar resorption when all GCTB samples were analysed together. However, in a subset of GCTBs, the 
DISCUSSION
In this study we have shown that the growth factors VEGF-A, VEGF-D, PlGF, FL and HGF are capable of substituting for M-CSF to support RANKL-induced human monocyte-osteoclast differentiation. Multinucleated cells expressing the cytochemical and functional markers of osteoclasts were formed when these growth factors were added to monocyte cultures, even in the presence of an anti-M-CSF neutralising antibody. Osteoclast resorption was less than that seen in M-CSF and RANKL-treated cultures but a marked increase in osteolysis was noted when VEGF and HGF were added to M-CSF/RANKL-treated monocyte cultures with the formation of giant, hyper-multinucleated and hyper-resorptive osteoclasts, similar to those seen in GCTB.
Multinucleated cells which formed in CD14 þ monocyte cultures to which VEGF-A, VEGF-D, PlGF, FL or HGF were added expressed characteristic markers of mature osteoclasts including TRAP, CD51, F-actin rings and the ability to carry out lacunar resorption. These findings suggest that these growth factors may have a role in compensating for the absence of M-CSF in op/op mice, which have a mutation in the coding region of the M-CSF gene that results in an osteopetrotic phenotype. 6, 7 It is known that a few osteoclasts can be identified in bones of these osteopetrotic mice and that this defect, can partially correct itself with age. 14, 15 The above growth factors may thus provide a salvage pathway for osteoclast formation that could explain this observation. The cytokine Interleukin 34, which has also recently been shown to bind to the M-CSF receptor and to have a role in osteoclastogenesis, is also expressed in GCTB. 23, 24 The cytokine interleukin 34, which has also recently been shown to react with the M-CSF receptor and to have a role in osteoclastogenesis, is also expressed in GCTB. 23, 24 Conflicting evidence exists as to whether VEGF-A can support osteoclast formation. [17] [18] [19] 21, 22 Our findings are in agreement with studies showing that VEGF-A can correct the defect in op/op mice and support a role for VEGF-A in osteoclast formation. Although VEGF-A has previously been reported to support human osteoclast formation in vitro by Aldridge et al, 21 this was not conclusively shown as osteoclastogenesis was not determined in the presence of an anti-M-CSF antibody and resorption was noted in negative control cultures. This study also noted that VEGF-A-and M-CSF-induced osteoclastogenesis effected a similar level of resorption. We noted that osteoclasts formed in VEGF-Atreated cultures were capable of much less resorption (7.5% relative to M-CSF-treated cultures) and did not observe a difference in the number of TRAP þ multinucleated cells. Osteoclast formation and lacunar resorption in our M-CSFtreated cultures was considerably more (65-80% compared with 4-8%) than in the study of Aldridge et al. 21 FL has previously been shown in vitro to support osteoclast formation independently of M-CSF in mice (including op/ op mice), but not in man. 17, 21 Our findings indicate that FL can support human osteoclast formation; less resorption and fewer osteoclasts were observed compared with M-CSFtreated cultures. Our findings also confirm previous studies, which showed that HGF can support human osteoclast formation. 16 Aldridge et al 21 also reported that VEGF-D and PlGF are capable of substituting for M-CSF in osteoclast formation. They found that, relative to VEGF-A, significantly fewer resorption pits were formed in VEGF-D-and PlGF-treated cultures, and that in VEGF-D treated cultures this was associated with fewer TRAP þ cells. In the present study we did not observe a significant difference in the number of TRAP þ cells or lacunar resorption in VEGF-D-or PlGFtreated cultures compared with VEGF-A-treated cultures. PIGF has been shown to have a role in bone remodelling and osteoclast differentiation. 25 The addition of an anti-PIGF antibody has been shown to reduce the osteolysis in metastatic tumours. 26 PIGF is a homologue of VEGF-C; both are RANKL targets and mediate RANKL activity. 27 We found, however, that VEGF-C was not able to support human osteoclast formation independent of M-CSF. RANKL enhances the expression of VEGF-C mRNA and overexpression of VEGF-C increases resorption activity four-fold. 27 VEGF-C binds to VEGFR2 and VEGFR3, and osteoclasts have been shown to express VEGFR3; it is possible that VEGF-C mediates its effects largely through VEGFR2 rather than VEGFR3.
In general, VEGF-A, VEGF-D, PlGF, FL and HGF exhibited a similar capacity to act as M-CSF substitutes in osteoclast formation: these growth factors produced similar numbers of TRAP þ multinucleated cells that effected a similar amount of lacunar resorption. When VEGF-A, HGF and M-CSF were added to monocyte cultures, however, this resulted in the formation of giant, hyper-nucleated osteoclasts, which showed markedly increased lacunar resorption (1.7-fold more than control M-CSF/RANKL-treated cultures). The very large hyper-nucleated osteoclasts formed in the presence of MVHR were similar in cytomorphology to the osteoclastic giant cells of GCTB, a tumour which is markedly osteolytic. Immunohistochemical findings confirmed that M-CSF, HGF and VEGF (as well as FL and PlGF) are all present in GCTB. 
Osteoclastogenesis by M-CSF substitutes RM Taylor et al
The presence of these osteoclastogenic growth factors may in part explain the giant cell-rich nature and aggressive osteolysis of GCTB. Both the multinucleated and mononuclear cell population in GCTB expressed M-CSF and M-CSF substitutes. The expression of osteoclastogenic factors by giant cells may represent a positive feedback autocrine mechanism that promotes osteoclast recruitment and formation in GCTB. 28 Expression of osteoclastogenic factors by GCTB mononuclear cells is in keeping with the hypothesis that these cells express growth factors promoting osteoclast formation. 20, 29 VEGF-A and RANKL expression by GCTB giant cells and M-CSF expression in enriched cultures of GCTB giant cells has been reported in previous studies. 30 Previous work has shown that M-CSF can inhibit or stimulate osteoclast resorption activity depending on the resorption model and species of osteoclast employed. [11] [12] [13] 31 The effect of both M-CSF and M-CSF substitutes on GCTBderived osteoclasts has not been previously investigated. M-CSF is known to stimulate osteoclast migration and it has been proposed that this is associated with the disassembly of the resorption machinery. 32 We found that M-CSF alone did not inhibit the resorption activity of osteoclasts derived from most GCTBs. In fact, a stimulatory effect on resorption was seen in a minority of GCTBs, which clinically and morphologically were not obviously different from other (unstimulated) GCTBs. M-CSF substitutes also had a stimulatory effect on resorption in this group of tumours. Little work has been done on the effect of the M-CSF substitute growth factors on osteoclast resorption. VEGF has been shown to enhance resorption in cultures of rabbit osteoclasts 33 and HGF in rat osteoclast-osteoblast cocultures, whereas FL did not effect murine osteoclast resorption activity. 34 Our preliminary results show an inhibitory effect of Imatinib and Sunitinib on osteoclast resorption in short-term cultures of two giant cell tumours.
The complex growth factor environment found in GCTB (and other giant cell-rich lesions of bone and joint) is likely to have a role in determining the pathological features and the extent of resorption, which characterise this tumour. Our findings indicate that VEGF-A, VEGF-D, PlGF, FL and HGF are capable of acting as M-CSF substitutes in osteoclastogenesis. These growth factors are expressed in GCTB and in specific growth factor combinations, possibly in concert with IL-34, 23 may result in the formation of GCTB-like hypernucleated osteoclasts capable of lacunar resorption. M-CSF and M-CSF substitute growth factors also stimulated osteoclast resorption in a subset of GCTBs. In addition to other features of GCTB, such as increased vascularity and tumour progression, 20 these growth factors could explain in part the cytomorphology of GCTB giant cells and the osteolytic behaviour of this tumour.
